TrakCel & McKesson partner to help commercialize gene & cell therapy

By Nikita Chaurasia  Date: 2019-09-13

TrakCel & McKesson partner to help commercialize gene & cell therapy
  • The combination of these two product suites is designed specifically for the growing number of developers that are nearing the commercial launch of gene and cell therapies.
  • The integrated platform allows the product scale-up towards market delivery including automatic product-specific workflow scheduling across multiple care team members and supply chain partners.

McKesson, a leading provider of patient access support, third-party logistic (3PL) services as well as specialty pharmacy solutions, and TrakCel, software developing firm for gene and cell therapy orchestration and supply chain tracking systems, reportedly announced a collaboration to help late-stage developers of gene and cell therapy.

The collaboration will combine both companies’ patient access services and supply chain tracking to allow a more effective path for the industry players to develop next-gen commercial therapies.

Integrating TrakCel’s personalized drug orchestration software and data tracking system with the capabilities of McKesson’s current high-touch platform for patients, as well as both the companies’ support and expertise, will give an end-to-end solution for the gene and cell therapy industry to manage the entirety of the therapeutic supply chain.

McKesson and TrakCel would start by developing a basic solution design. Both these integrated solutions will further be offered to individual company clients which would then benefit specifically from this combined solution.

The combination of these two product suites is particularly designed for the growing number of developers that are approaching commercial launch of their gene and cell therapies. The integrated platform allows the product scale-up towards market delivery.

This also involves automated scheduling of product-centric workflows across numerous care team members and supply chain partners, and a validated tracking of chain-of-identity to ensure delivery of the right drug product. These capabilities guarantee that the patient gets the right, uncompromised treatment at the correct time.

Layne Martin, VP/GM of Specialty Distribution Solutions at McKesson Life Sciences stated that the integrated system would help manufacturers and prescribers work together in a seamless manner to ensure that right patient always gets the right therapeutic product and at the correct time.

Source credit: https://www.businesswire.com/news/home/20190911005059/en/McKesson-TrakCel-Launch-Innovative-Collaboration-Support-Commercialization

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

India’s Gennova Biopharmaceutical working on Omicron-specific vaccine

By Nikita Chaurasia

Gennova's potential mRNA vaccine is currently undergoing Phase II and Phase III trials. If approved for a EUA, it would be India’s first mRNA COVID-19 vaccine. Gennova Biopharmaceutical, a subsidiary of Pune-based drugmaker Emcure, is...

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

Recykal secures USD 22 Mn in a fundraise led by Morgan Stanley India

By Nikita Chaurasia

Recykal, a B2B waste management and recycling marketplace head-quartered in Hyderabad, has reportedly raised USD 22 million in funding from Morgan Stanley India. According to the company, existing investors including Circulate Capital, Arun Venkatac...

Reliance buys controlling stake in NYC hotel in its hospitality push

Reliance buys controlling stake in NYC hotel in its hospitality push

By Nikita Chaurasia

Reliance Industries Ltd. is reportedly planning to acquire a controlling stake in New York's five-star Mandarin Oriental Hotel for around USD 100 million. The company stated in a stock exchange filing that its industrial investments subsidiary, ...

India inoculates 3.8 million teens over fears of third COVID-19 wave

India inoculates 3.8 million teens over fears of third COVID-19 wave

By Nikita Chaurasia

India has reportedly vaccinated over 3.8 million teens aged between 15-18 years as of 3rd January in an effort to boost its inoculation drive to protect the large young population before the onslaught of a possible third wave of coronavirus infection...

Apple on track to become the world’s first USD 3 trillion company

Apple on track to become the world’s first USD 3 trillion company

By Nikita Chaurasia

Tech giant Apple Inc. has once again become the world’s most valuable company as it is just a hair's breadth away from a market capitalization of USD 3 trillion. On Monday, the iPhone maker’s shares slid a little over 2% to USD 175.7...